Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Sanofi (NASDAQ:SNY) ranks among the best medical stocks to buy according to analysts. On July 25, Sanofi (NASDAQ:SNY) ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decrease 25% in ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Sanofi reports strong Q2 2025 growth with innovative launches like Dupixent and strategic acquisitions boosting sales.

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...